Arch Biopartners Aktie - ARCH

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Premium

Current Price

1,83

Gebot

1,83

Fragen

1,85

Volumen

7.600

1,80 Tagesbereich 1,88

0,00 52-Wochen-Bereich 0,00

Marktkapitalisierung

114,554M

Handelsende

1,88

Handelsbeginn

1,88

Letzte Trade

100

1.83

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

Ausgegebene Aktien

62.598.000

Dividendenrendite

Kurs-Gewinn-Verhältnis

-34,46

Gewinn pro Aktie (EPS)

-0,05

Erlöse

1,98M

Nettogewinn

-3,33M

Sektor

Coml Physical, Biologcl Resh

Branche

Advertising Agencies

Website

archbiopartners.com

Hauptsitz

Toronto, Ontario, Can

Gegründet

2010

Arch Biopartners Inc is listed in the Coml Physical, Biologcl Resh sector of the TSX Venture Börse with ticker ARCH. The last closing price for Arch Biopartners was $1,88. Over the last year, Arch Biopartners shares have traded in a share price range of $ 0,00 to $ 0,00.

Arch Biopartners currently has 62.598.000 shares in issue. The market capitalisation of Arch Biopartners is $117,68 million. Arch Biopartners has a price to earnings ratio (PE ratio) of -34.46.

Arch Biopartners Announces Ontario Research Ethics Board Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)

TORONTO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University Health Network Research...

Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

TORONTO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient recruitment and dosing have begun...

Arch Biopartners Arranges Non-Brokered Private Placement

TORONTO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has arranged a non-brokered private placement...

Closes Units for Debt Settlement

TORONTO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company has closed a transaction that...

Units for Debt Settlement

TORONTO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company has arranged a transaction to...

Arch Biopartners Announces Alberta Health Services Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)

TORONTO, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that Alberta Health Services (AHS) has approved...

Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins

Arch is repurposing cilastatin, a dipeptidase-1 inhibitor, as a new treatment for acute kidney injury (AKI)Cilastatin is particularly well suited to prevent AKI caused by drug toxins due to its...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

ARCH - Frequently Asked Questions (FAQ)

What is the current Arch Biopartners share price?

The current share price of Arch Biopartners is $ 1,83

How many Arch Biopartners shares are in issue?

Arch Biopartners has 62.598.000 shares in issue

What is the market cap of Arch Biopartners?

The market capitalisation of Arch Biopartners is CAD 117,68M

What is the 1 year trading range for Arch Biopartners share price?

Arch Biopartners has traded in the range of $ 0,00 to $ 0,00 during the past year

What is the PE ratio of Arch Biopartners?

The price to earnings ratio of Arch Biopartners is -34,46

What is the cash to sales ratio of Arch Biopartners?

The cash to sales ratio of Arch Biopartners is 57,73

What is the reporting currency for Arch Biopartners?

Arch Biopartners reports financial results in CAD

What is the latest annual turnover for Arch Biopartners?

The latest annual turnover of Arch Biopartners is CAD 1,98M

What is the latest annual profit for Arch Biopartners?

The latest annual profit of Arch Biopartners is CAD -3,33M

What is the registered address of Arch Biopartners?

The registered address for Arch Biopartners is 27 ST. CLAIR AVENUE EAST, P.O. BOX 305, TORONTO, ONTARIO, M5V 1M1

What is the Arch Biopartners website address?

The website address for Arch Biopartners is archbiopartners.com

Which industry sector does Arch Biopartners operate in?

Arch Biopartners operates in the ADVERTISING AGENCIES sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
BYM.HBaymount Incorporated	$ 0,015 (200,00%)	102k
FBR.HFibre Crown Manufacturing Inc	$ 0,12 (140,00%)	10k
MPTH.HMapath Capital Corp	$ 0,035 (133,33%)	1.000
MMNMonarca Minerals Inc	$ 0,01 (100,00%)	10k
GETTGETT Gold Inc	$ 0,02 (100,00%)	1,1k
EKGCardioComm Solutions Inc	$ 0,01 (-50,00%)	79k
ADEAdex Mining Inc	$ 0,005 (-50,00%)	21,1k
MVYMoovly Media Inc	$ 0,005 (-50,00%)	1,3M
MURMurchison Minerals Ltd	$ 0,01 (-33,33%)	10k
AOROAloro Mining Corp	$ 0,01 (-33,33%)	59k
GXUGoviEx Uranium Inc	$ 0,035 (-30,00%)	50,83M
AISXAisix Solutions Inc	$ 0,05 (42,86%)	6,56M
CYGCygnus Metals Limited	$ 0,12 (-7,69%)	4,8M
GPUSAlset AI Ventures Inc	$ 0,105 (10,53%)	4,43M
QNCQuantum Emotion Corp	$ 0,81 (6,58%)	3,16M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Arch Biopartners Inc (ARCH)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

Über Arch Biopartners Inc

ARCH Neueste Nachrichten

Arch Biopartners Announces Ontario Research Ethics Board Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)

Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Arch Biopartners Arranges Non-Brokered Private Placement

Closes Units for Debt Settlement

Units for Debt Settlement

Arch Biopartners Announces Alberta Health Services Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)

Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins

Arch Biopartners Closes Non-Brokered Private Placement

Arch Biopartners Arranges Non-Brokered Private Placement

Arch Biopartners Announces GMP Manufacturing of Cilastatin Drug Product

Arch Biopartners Announces Ontario Research Ethics Board Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)

Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Arch Biopartners Arranges Non-Brokered Private Placement

Closes Units for Debt Settlement

Units for Debt Settlement

Arch Biopartners Announces Alberta Health Services Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)

Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins

Arch Biopartners Closes Non-Brokered Private Placement

ARCH - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Arch Biopartners Inc (ARCH) Börsenkurse

Arch Biopartners Inc (ARCH)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

Über Arch Biopartners Inc

ARCH Neueste Nachrichten

ARCH - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS